A single‐center, open‐label, randomized cross‐over study to evaluate the pharmacokinetics and bioavailability of once‐daily prolonged‐release formulations of tacrolimus in de novo liver transplant recipients

BACKGROUND: The narrow therapeutic window of tacrolimus (Tac) requires intense drug monitoring to achieve adequate efficacy while minimizing dose‐related toxicities. Once‐daily formulations of Tac (LCP‐Tac and PR‐Tac) have been recently designed for higher bioavailability and a more consistent expos...

Descripción completa

Detalles Bibliográficos
Autores principales: Herden, Uta, Sterneck, Martina, Buchholz, Bettina M., Achilles, Eike G., Ott, Armin, Fischer, Lutz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589356/
https://www.ncbi.nlm.nih.gov/pubmed/34559956
http://dx.doi.org/10.1002/iid3.537

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589356/
https://www.ncbi.nlm.nih.gov/pubmed/34559956
http://dx.doi.org/10.1002/iid3.537

Ejemplares similares